Financing ·
Legend Biotech Corporation entered into an Underwriting Agreement on June 17, 2026, for a public offering of 7,700,000…
LEGNLegend Biotech Corp
Legend Biotech Corporation entered into an Underwriting Agreement on June 17, 2026, for a public offering of 7,700,000 American Depositary Shares (ADSs), representing 15,400,000 ordinary shares, at $29.35 per ADS. The offering is expected to close on or about June 23, 2026, and is expected to yield net proceeds of approximately $211.6 million. Legend Biotech Corporation is a biotechnology company focused on developing and commercializing cell therapies.